Episurf Medical AB (publ) (EPIS-B.ST)
SEK 0.13
(-2.03%)
SEK 0.13
(-2.03%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 10.3 Million SEK | 56.06% |
| 2022 | 6.6 Million SEK | 1.54% |
| 2021 | 6.5 Million SEK | 30.0% |
| 2020 | 5 Million SEK | 2.04% |
| 2019 | 4.9 Million SEK | 22.5% |
| 2018 | 4 Million SEK | 60.63% |
| 2017 | 2.49 Million SEK | 3.52% |
| 2016 | 2.4 Million SEK | 136.67% |
| 2015 | 1.01 Million SEK | 487.46% |
| 2014 | 173.02 Thousand SEK | 356.34% |
| 2013 | 37.91 Thousand SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 3.2 Million SEK | 3.23% |
| 2024 Q3 | 3.4 Million SEK | 6.25% |
| 2024 Q1 | 3.1 Million SEK | 6.9% |
| 2023 Q3 | 2.6 Million SEK | 18.18% |
| 2023 FY | 10.3 Million SEK | 56.06% |
| 2023 Q2 | 2.2 Million SEK | -12.0% |
| 2023 Q4 | 2.9 Million SEK | 11.54% |
| 2023 Q1 | 2.5 Million SEK | 38.89% |
| 2022 Q2 | 1.9 Million SEK | 18.75% |
| 2022 FY | 6.6 Million SEK | 1.54% |
| 2022 Q1 | 1.6 Million SEK | 14.29% |
| 2022 Q4 | 1.8 Million SEK | 28.57% |
| 2022 Q3 | 1.4 Million SEK | -26.32% |
| 2021 Q3 | 1.5 Million SEK | -25.0% |
| 2021 FY | 6.5 Million SEK | 30.0% |
| 2021 Q2 | 2 Million SEK | 25.0% |
| 2021 Q4 | 1.4 Million SEK | -6.67% |
| 2021 Q1 | 1.6 Million SEK | 6.67% |
| 2020 FY | 5 Million SEK | 2.04% |
| 2020 Q3 | 1.5 Million SEK | 150.0% |
| 2020 Q4 | 1.5 Million SEK | 0.0% |
| 2020 Q2 | 600 Thousand SEK | -60.0% |
| 2020 Q1 | 1.5 Million SEK | 15.38% |
| 2019 FY | 4.9 Million SEK | 22.5% |
| 2019 Q1 | 1.4 Million SEK | 27.27% |
| 2019 Q2 | 1.1 Million SEK | -21.43% |
| 2019 Q3 | 1.1 Million SEK | 0.0% |
| 2019 Q4 | 1.3 Million SEK | 18.18% |
| 2018 Q4 | 1.1 Million SEK | 10.0% |
| 2018 FY | 4 Million SEK | 60.63% |
| 2018 Q2 | 800 Thousand SEK | -27.27% |
| 2018 Q3 | 1 Million SEK | 25.0% |
| 2018 Q1 | 1.1 Million SEK | 24.42% |
| 2017 Q3 | 520.28 Thousand SEK | -16.47% |
| 2017 Q2 | 622.89 Thousand SEK | 34.54% |
| 2017 Q4 | 884.08 Thousand SEK | 69.92% |
| 2017 Q1 | 462.97 Thousand SEK | -54.06% |
| 2017 FY | 2.49 Million SEK | 3.52% |
| 2016 Q4 | 1 Million SEK | 95.06% |
| 2016 Q3 | 516.64 Thousand SEK | 10.07% |
| 2016 Q1 | 411.83 Thousand SEK | 9.71% |
| 2016 Q2 | 469.38 Thousand SEK | 13.97% |
| 2016 FY | 2.4 Million SEK | 136.67% |
| 2015 Q3 | 150.17 Thousand SEK | -43.1% |
| 2015 Q1 | 227.01 Thousand SEK | 316.22% |
| 2015 Q4 | 375.36 Thousand SEK | 149.96% |
| 2015 FY | 1.01 Million SEK | 487.46% |
| 2015 Q2 | 263.9 Thousand SEK | 16.25% |
| 2014 Q3 | 78.23 Thousand SEK | 253.09% |
| 2014 FY | 173.02 Thousand SEK | 356.34% |
| 2014 Q2 | 22.15 Thousand SEK | 22.46% |
| 2014 Q1 | 18.09 Thousand SEK | -52.28% |
| 2014 Q4 | 54.54 Thousand SEK | -30.29% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 FY | 37.91 Thousand SEK | 0.0% |
| 2013 Q4 | 37.91 Thousand SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 Q1 | - SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2010 Q2 | 486.03 Thousand SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2010 Q1 | - SEK | 0.0% |
| 2010 Q3 | - SEK | -100.0% |
| 2009 FY | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -65.038% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 99.25% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 99.25% |
| Arcoma AB | 163.01 Million SEK | 93.682% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | 94.951% |
| BICO Group AB (publ) | 2.23 Billion SEK | 99.54% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 98.197% |
| CellaVision AB (publ) | 677.29 Million SEK | 98.479% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | -24.501% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -955.024% |
| C-Rad AB (publ) | 424.61 Million SEK | 97.574% |
| Duearity AB (publ) | 1.65 Million SEK | -522.733% |
| Dignitana AB (publ) | 86.06 Million SEK | 88.032% |
| Getinge AB (publ) | 31.82 Billion SEK | 99.968% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | -45.515% |
| Integrum AB (publ) | 104.11 Million SEK | 90.107% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -1105.103% |
| Mentice AB (publ) | 273.61 Million SEK | 96.236% |
| OssDsign AB (publ) | 112.15 Million SEK | 90.816% |
| Paxman AB (publ) | 210.11 Million SEK | 95.098% |
| Promimic AB (publ) | 37.07 Million SEK | 72.215% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -4121.311% |
| SciBase Holding AB (publ) | 23.24 Million SEK | 55.689% |
| ScandiDos AB (publ) | 60.42 Million SEK | 82.955% |
| Sectra AB (publ) | 2.96 Billion SEK | 99.652% |
| Sedana Medical AB (publ) | 153.86 Million SEK | 93.306% |
| Senzime AB (publ) | 35.75 Million SEK | 71.192% |
| SpectraCure AB (publ) | 318 Thousand SEK | -3138.994% |
| Stille AB | 294.89 Million SEK | 96.507% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 99.707% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 98.276% |